Table 1.
Demographic characteristics of patients
| Characteristics | Value |
|---|---|
| Age (years) (mean ± SD; range) | 35.6 ± 11.5 (14–65) |
| Gender | |
| Male | 19 (76%) |
| Female | 6 (24%) |
| Metastases | |
| None | 5 (20%) |
| Lymph nodes | 13 (52%) |
| Skeletal | 13 (52%) |
| Liver | 3 (12%) |
| Lungs | 3 (12%) |
| Prior treatment | |
| Yes | 19 (76%) |
| No | 6 (24%) |
| Type of prior therapies | |
| Surgery | 14 (56%) |
| Chemotherapy | 5 (20%) |
| Radiotherapy | 4 (16%) |
| 131I-MIBG therapy | 2 (8%) |
| Inoperable/no treatment affected | 6 (24%) |
| Disease status at baseline | |
| Progressive disease | 21 (84%) |
| Stable disease | 4 (16%) |
| Anti-hypertensive drugs | 14 (56%) |
| Number of 177Lu-DOTATATE therapy cycles (median, range) | 3 (2–8) |
| Treatment duration | |
| Median (range) | 30 (15–96) |
| Cumulative activity (GBq) | 22.86 ± 9.54 (14.43–50) |